Intercept Pharmaceuticals and the whole Nash field await Ocaliva’s pivotal readout.
Merck & Co awaits full Keynote-426 data with Keytruda plus Inlyta, while Seattle Genetics looks beyond Adcetris with enfortumab vedotin.
Tiny signs of a therapeutic benefit are offset by safety worries, as the company pivots to higher doses and second-generation projects.
Solid Biosciences’ muscular dystrophy gene therapy fails to hit the company’s own target, let alone a benchmark set by Sarepta.
Positive progression-free survival results in breast cancer for the company’s lead asset, margetuximab, take the markets by surprise.
The company’s nascent CAR-T portfolio includes technology licensed from one of the field’s most prominent pioneers.
But Erleada, Johnson & Johnson’s next-gen prostate cancer therapy, still needs to outperform the incumbent, Zytiga.
The Biotime-backed group believes it can use immune system gene expression levels to detect lung cancer earlier. But another trial will be necessary before the test can…
Data from quad therapy and a subcutaneous formulation could resuscitate enthusiasm even if the US government shutdown delays Darzalex's upcoming first-line approval.